MedTrace Logo

Effect of Different Antihypertensive Drugs on Central Blood Pressure

NCT05328310 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2022-04-14

No results posted yet for this study

Summary

Trial name) The differential effects of antihypertensive drugs on central blood pressure: comparison between beta-blocker(BB) and angiotensin receptor blocker ARB)

Objectives) To evaluate the effect of BB, which has vasodilatory effects, on CBP by comparison between ARB, one of the most widely used class of antihypertensives.

Study design) A multicenter, prospective, randomized, controlled, open-label clinical trial for hypertension patients.

Patient enrollment) 110 patients will be enrolled at 2 centers in South Korea.

Patient follow-up) Patients will go through an initial washout period of two weeks prior to randomization. After pre-medication baseline visit and randomization, clinical follow-up will occur at 4, 8, 12 weeks after initial administration of randomized drug. The follow-up visits are office visits.

Primary endpoint) Reduction in CBP at 12 weeks.

Secondary endpoints) Clinical events including adverse reactions to the drugs.

Conditions

Interventions

DRUG

Nebivolol

Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.

Sponsors & Collaborators

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Cheol Woong Yu, M.D. Ph.D · Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-06
Primary Completion
2022-12-31
Completion
2026-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05328310 on ClinicalTrials.gov